|
PF-55729 |
NEUROTROPAS Lamfer 25,000 Solución inyectable |
2023-08-30 |
|
Laboratorios Lamfer |
Guatemala
|
Med Pharma |
Servicio De Comercio Internacional |
Selectpharma |
Bodega Farmacéutica, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-55801 |
PREDNISOLONA Selectpharma 15 mg/5 mL Solución oral |
2023-09-17 |
|
Selectpharma |
Guatemala
|
Med Pharma |
Servicio De Comercio Internacional |
Selectpharma |
Bodega Farmacéutica, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-56179 |
SPIROCARD 25 mg Tableta recubierta |
2023-12-19 |
|
Med Pharma |
Guatemala
|
Med Pharma |
Servicio De Comercio Internacional |
Selectpharma |
Bodega Farmacéutica, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-56335 |
SITALEV MET 50 mg / 500 mg Tableta recubierta |
2024-01-29 |
|
Med Pharma |
Guatemala
|
Med Pharma |
Servicio De Comercio Internacional |
Selectpharma |
La Botica |
Bodega Farmacéutica, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-56353 |
SITALEV 100 mg Tableta recubierta |
2024-02-01 |
|
Med Pharma |
Guatemala
|
Med Pharma |
Servicio De Comercio Internacional |
Selectpharma |
La Botica |
Bodega Farmacéutica, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-56494 |
PREDNICET 5 mg Tabletas |
2024-03-22 |
|
Med Pharma |
Guatemala
|
Med Pharma |
Servicio De Comercio Internacional |
Selectpharma |
Bodega Farmacéutica, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-56351 |
SITALEV MET 50 mg / 1000 mg Tableta recubierta |
2024-01-31 |
|
Med Pharma |
Guatemala
|
Med Pharma |
Servicio De Comercio Internacional |
Selectpharma |
La Botica |
Bodega Farmacéutica, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-57069 |
ARES 250 mg/5 mL Polvo para suspensión oral |
2024-08-09 |
|
Dogma |
Guatemala
|
Dogma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-55805 |
ARES 375 mg Tableta recubierta |
2023-09-18 |
|
Dogma |
Guatemala
|
Dogma |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-55806 |
ROSUVASTATINA Selectpharma 20 mg Tabletas recubiertas |
2023-09-18 |
|
Med Pharma |
Guatemala
|
Med Pharma |
Servicio De Comercio Internacional |
Selectpharma |
Bodega Farmacéutica, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|